Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study
- Equal contributors
1 Division of Epidemiology, School of Public Health, University of California, Berkeley, USA
2 Preventive Medicine Department, School of Medicine, University of São Paulo, Brazil
3 Social Medicine Department, School of Medical Sciences of Santa Casa of São Paulo, Brazil
4 Emilio Ribas Infectious Diseases Institute, São Paulo State Health Department, São Paulo, Brazil
BMC Infectious Diseases 2007, 7:119 doi:10.1186/1471-2334-7-119Published: 23 October 2007
Polysaccharide pneumococcal vaccine is recommended for use in HIV-infected adults in Brazil but there is uncertainty about its effectiveness in this patient population.
The main objective of this study was to assess the effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal infection among HIV-infected adult patients in São Paulo, Brazil.
A case-control study of 79 cases and 242 controls matched on CD4+ cell count and health care setting was conducted. Among HIV-infected adults in São Paulo, Brazil, with and without
After adjustment for confounding factors, the point estimate for the effectiveness of 23 valent polysaccharide vaccine among HIV-infected adults against all invasive pneumococcal infection was 18% (95% CI: <0 to 62%).
We were unable to demonstrate a statistically significant protective effect of 23 valent polysaccharide against invasive pneumococcal infection vaccine among HIV-infected adults in Brazil.
While the vaccine is relatively inexpensive and safe, its effectiveness among HIV-infected adults in Brazil is uncertain.